Literature DB >> 24498555

The desmoplastic stroma of pancreatic cancer is a barrier to immune cell infiltration.

Jennifer Watt1, Hemant M Kocher1.   

Abstract

A detailed map demonstrating the spatially restricted distribution of immune cells within the desmoplastic stroma of human pancreatic tumors opens up the field of pancreatic oncoimmunology. CD8+ T cells located in the proximity of malignant lesions are associated with a survival advantage, suggesting the existence of immunoediting. Pancreatic stellate cells appear to dictate the infiltration of the juxtatumoral stroma by CD8+ T cells.

Entities:  

Keywords:  B cells; CD8+ T cells; macrophages; natural killer cells; neutrophils

Year:  2013        PMID: 24498555      PMCID: PMC3912010          DOI: 10.4161/onci.26788

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


Pancreatic ductal adenocarcinomas (PDACs) are characterized by a dense desmoplastic reaction, primarily reflecting the activation of pancreatic stellate cells (PSC) driven by cancer cells. Non-transformed, healthy pancreatic tissues contain low amounts of PSCs in a quiescent state. In this setting, PSCs contain vitamin A droplets and have a limited ability to proliferate, migrate, and secrete extracellular matrix proteins., As a result of tissue injury, PSCs become activated in response to growth factors, oxidative stress, and change in tissue plasticity. Such activated PSCs lose their cytoplasmic vitamin A droplets, adopt a myofibroblastic phenotype, produce large amounts of extracellular matrix proteins, and exhibit increased migratory and proliferative activity. In these conditions, PSCs not only stimulate the proliferation of pancreatic cancer cells and their invasive potential, but also inhibit their apoptotic demise through a multitude of signaling pathways. The activation of PSCs is reversible, even in presence of malignant cells, and hence potentially important from a therapeutic standpoint. LSL-Kras (KPC) mice provide a spontaneous model of PDAC that mimics several features of the human disease, including the representative desmoplastic stroma. When KPC mice were treated with all-trans retinoic acid (ATRA), the desmoplastic stroma collapsed along with the inhibition of tumor growth.ATRA efficiently restores retinol depots within PSCs in vivo, rendering them quiescent. The failure of many chemotherapeutics to provide benefits to pancreatic cancer patients despite their efficacy against epithelial cancer cells in vitro has been attributed to the fact that many researchers have failed to recognize the protective effects of the desmoplastic stroma. This dense stroma is being recognized to comprise distinct morphological and functional compartments, as evidenced by independent work from different laboratories., For example, the gene expression pattern of stromal components has been show to differ depending on their proximity to malignant cells. In particular, the juxtatumoral stroma (the stromal component that is juxtaposed to malignant cells) exhibits a distinct gene expression profiles as compared with other stromal compartments (panstroma). In the setting of inflammation and fibrosis, hepatic stellate cells (HSCs) have been shown to act as antigen-presenting cells and interact with CD1- as well as MHC class I- and MHC class II-restricted T cells. Thus, HSCs can present lipid antigens to natural killer (NK) cells, stimulating their proliferation, as well as antigenic peptides to CD8+ and CD4+ T cells, resulting in the cross-priming of the former. However, to date no such interaction has been reported between PSCs and T cells. Most often, the infiltration of neoplastic lesions by CD8+ T lymphocytes is associated with improved prognosis. We have recently investigated the global and compartment-specific immune infiltrate of human pancreatic cancer, as compared with other pancreatic disorders, using an unbiased automated system. We unveiled for the first time a PDAC-specific and compartment-specific immune cell infiltrative defect. In particular, neoplastic tissues, in particular those associated with poor prognosis (i.e., from cases of PDAC and cholangiocarcinoma), were infiltrated by immune cells of all types, with the standalone exception of CD8+ cytotoxic T cells, to greater extents than benign tissues. Indeed, CD8+ T cells were found to infiltrate PDAC lesions in amounts that were comparable to those observed in chronic pancreatitis but significantly lower than those detected in other malignant pancreatico-biliary (PB) conditions. Similar findings have been obtained with KPC mice. The most intriguing of our findings was that we observed a stromal compartment-specific, as opposed to generalized, infiltrative defect. In particular, we found that CD8+ T cells, CD20+ B cells, CD56+ NK cells, and FOXP3+ regulatory T cells (T cells) are unable to sufficiently infiltrate the juxtatumoral stroma of PDAC lesions (Fig. 1). Conversely, other cells of the innate immune system such as CD68+ macrophages and myeloperoxidase-expressing neutrophils could infiltrate this compartment. Of note, PDAC patients harboring high amounts of CD8+ T cells in the juxtatumoral stroma exhibited improved survival. We could recapitulate most of these findings in KPC mice. Upon the administration of ATRA to KPC mice (resulting in the quiescence of PSCs), we observed a reversal of the juxtatumoral exclusion of CD8+ T cells. Conversely, no difference in the distribution of other immune cell subsets was detected in response to ATRA. These observations suggest that activated PSCs in the panstroma selectively sequester immune cells. These findings fit nicely with the results obtained by Winau et al. relative to the interplay between CD8+ T cells, NK cells and HSCs in the course of hepatic inflammation. While we did not exhaustively investigate all the functional interactions between PSCs and immune cells including NK cells, MDSCs (myeloid-derived suppressor cells) and others, our findings provide a vivid picture of the human PDAC microenvironment for other researchers to build their hypotheses and investigate such a complex crosstalk.

Figure 1. Influence of ATRA on the immune cell subsets that infiltrate the stroma of pancreatic tumors. (A) The pancreatic ductal adenocarcinoma (PDAC) lesions developing in LSL-Kras (KPC) mice exhibit the same pattern of infiltration by immune cells observed in human PDAC tissues. In particular, the distribution of neutrophils and macrophages is homogeneous throughout the stromal compartments, while regulatory T cells (Tregs), cytotoxic CD8+ T cells and B cells are enriched in the panstromal compartment compared with the juxtatumoral stroma. (B) The administration of all-trans retinoic acid (ATRA) to these mice induces the quiescence of pancreatic stellate cell, resulting in an increased proportion of cytotoxic T cells within the juxtatumoral stroma.

Figure 1. Influence of ATRA on the immune cell subsets that infiltrate the stroma of pancreatic tumors. (A) The pancreatic ductal adenocarcinoma (PDAC) lesions developing in LSL-Kras (KPC) mice exhibit the same pattern of infiltration by immune cells observed in human PDAC tissues. In particular, the distribution of neutrophils and macrophages is homogeneous throughout the stromal compartments, while regulatory T cells (Tregs), cytotoxic CD8+ T cells and B cells are enriched in the panstromal compartment compared with the juxtatumoral stroma. (B) The administration of all-trans retinoic acid (ATRA) to these mice induces the quiescence of pancreatic stellate cell, resulting in an increased proportion of cytotoxic T cells within the juxtatumoral stroma. Our initial migration and adhesion experiments based on T cells and PSCs isolated from healthy individuals and PDAC patients confirmed the critical role of the activation state of PSC in altering the behavior of T cells. Chemokine C-X-C motif ligand 12 (CXCL12) was identified from our previous work as a potential inducer of such a functional alteration. Using recombinant CXCL12 and RNA interference we could demonstrate that, at least in this setting, the migration of T cells depend on CXCL12 secreted from PSCs, which may explain the in vivo sequestration that we observed. A number of other adhesion molecules and chemokines should be investigated for their ability to influence the spatial and temporal distribution of immune cells within PDAC lesions. Altogether, our findings demonstrate that activated PSCs within the PDAC stroma have an important impact on the migration of immune cells toward malignant lesions, perhaps orchestrating a hierarchy of interactions between immune cells and neoplastic cells. We have shown that CD8+ T lymphocytes found in the proximity of malignant cells confer a survival benefit to PDAC patients, and that their abundance can be increased by ATRA, owing to its ability to disrupt the juxtatumoral stroma. Thus, PSCs play an important role in the modulation of the crosstalk between neoplastic, stromal and immune cells, and need therefore to be considered as a therapeutic target in the context of combinatorial anticancer regimens.
  9 in total

Review 1.  What we have learned about pancreatic cancer from mouse models.

Authors:  Pedro A Pérez-Mancera; Carmen Guerra; Mariano Barbacid; David A Tuveson
Journal:  Gastroenterology       Date:  2012-03-08       Impact factor: 22.682

2.  Ito cells are liver-resident antigen-presenting cells for activating T cell responses.

Authors:  Florian Winau; Guido Hegasy; Ralf Weiskirchen; Stephan Weber; Cécile Cassan; Peter A Sieling; Robert L Modlin; Roland S Liblau; Axel M Gressner; Stefan H E Kaufmann
Journal:  Immunity       Date:  2007-01       Impact factor: 31.745

Review 3.  A starring role for stellate cells in the pancreatic cancer microenvironment.

Authors:  Minoti V Apte; Jeremy S Wilson; Aurelia Lugea; Stephen J Pandol
Journal:  Gastroenterology       Date:  2013-06       Impact factor: 22.682

Review 4.  The pancreas cancer microenvironment.

Authors:  Christine Feig; Aarthi Gopinathan; Albrecht Neesse; Derek S Chan; Natalie Cook; David A Tuveson
Journal:  Clin Cancer Res       Date:  2012-08-15       Impact factor: 12.531

5.  Stromal responses to carcinomas of the pancreas: juxtatumoral gene expression conforms to the infiltrating pattern and not the biologic subtype.

Authors:  Francesca Ricci; Scott E Kern; Ralph H Hruban; Christine A Iacobuzio-Donahue
Journal:  Cancer Biol Ther       Date:  2005-03-23       Impact factor: 4.742

6.  Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.

Authors:  Lauren J Bayne; Gregory L Beatty; Nirag Jhala; Carolyn E Clark; Andrew D Rhim; Ben Z Stanger; Robert H Vonderheide
Journal:  Cancer Cell       Date:  2012-06-12       Impact factor: 31.743

7.  Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes.

Authors:  Raghu Kadaba; Hanna Birke; Jun Wang; Steven Hooper; Claudia D Andl; Francesco Di Maggio; Erdinc Soylu; Mohammed Ghallab; Daniel Bor; Fieke Em Froeling; Satyajit Bhattacharya; Anil K Rustgi; Erik Sahai; Claude Chelala; Peter Sasieni; Hemant M Kocher
Journal:  J Pathol       Date:  2013-03-21       Impact factor: 7.996

8.  Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression.

Authors:  Fieke E M Froeling; Christine Feig; Claude Chelala; Richard Dobson; Charles E Mein; David A Tuveson; Hans Clevers; Ian R Hart; Hemant M Kocher
Journal:  Gastroenterology       Date:  2011-06-24       Impact factor: 22.682

9.  Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma.

Authors:  Abasi Ene-Obong; Andrew J Clear; Jennifer Watt; Jun Wang; Rewas Fatah; John C Riches; John F Marshall; Joanne Chin-Aleong; Claude Chelala; John G Gribben; Alan G Ramsay; Hemant M Kocher
Journal:  Gastroenterology       Date:  2013-07-25       Impact factor: 22.682

  9 in total
  31 in total

Review 1.  Kras and Tumor Immunity: Friend or Foe?

Authors:  Jane Cullis; Shipra Das; Dafna Bar-Sagi
Journal:  Cold Spring Harb Perspect Med       Date:  2018-09-04       Impact factor: 6.915

Review 2.  The pancreatic cancer microenvironment: A true double agent.

Authors:  Laleh G Melstrom; Marcela D Salazar; Don J Diamond
Journal:  J Surg Oncol       Date:  2017-06-12       Impact factor: 3.454

Review 3.  Targeting glycans for CAR therapy: The advent of sweet CARs.

Authors:  Zoe Raglow; Mary Kathryn McKenna; Challice L Bonifant; Wenjing Wang; Marina Pasca di Magliano; Johannes Stadlmann; Josef M Penninger; Richard D Cummings; Malcolm K Brenner; David M Markovitz
Journal:  Mol Ther       Date:  2022-07-12       Impact factor: 12.910

4.  Machine learning analyses of highly-multiplexed immunofluorescence identifies distinct tumor and stromal cell populations in primary pancreatic tumors.

Authors:  Krysten Vance; Alphan Alitinok; Seth Winfree; Heather Jensen-Smith; Benjamin J Swanson; Paul M Grandgenett; Kelsey A Klute; Daniel J Crichton; Michael A Hollingsworth
Journal:  Cancer Biomark       Date:  2022       Impact factor: 3.828

Review 5.  Emerging trends in the immunotherapy of pancreatic cancer.

Authors:  Kasturi Banerjee; Sushil Kumar; Kathleen A Ross; Shailendra Gautam; Brittany Poelaert; Mohd Wasim Nasser; Abhijit Aithal; Rakesh Bhatia; Michael J Wannemuehler; Balaji Narasimhan; Joyce C Solheim; Surinder K Batra; Maneesh Jain
Journal:  Cancer Lett       Date:  2017-12-12       Impact factor: 8.679

6.  Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma.

Authors:  Matthias Pinter; Arndt Weinmann; Marcus-Alexander Wörns; Florian Hucke; Simona Bota; Jens U Marquardt; Dan G Duda; Rakesh K Jain; Peter R Galle; Michael Trauner; Markus Peck-Radosavljevic; Wolfgang Sieghart
Journal:  United European Gastroenterol J       Date:  2017-02-26       Impact factor: 4.623

7.  Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma.

Authors:  Hao Liu; Kamila Naxerova; Matthias Pinter; Joao Incio; Hang Lee; Kohei Shigeta; William W Ho; Jonathan A Crain; Alex Jacobson; Theodoros Michelakos; Daniella Dias-Santos; Andrea Zanconato; Theodore S Hong; Jeffrey W Clark; Janet E Murphy; David P Ryan; Vikram Deshpande; Keith D Lillemoe; Carlos Fernandez-Del Castillo; Michael Downes; Ronald M Evans; James Michaelson; Cristina R Ferrone; Yves Boucher; Rakesh K Jain
Journal:  Clin Cancer Res       Date:  2017-06-09       Impact factor: 12.531

Review 8.  Re-engineering the Pancreas Tumor Microenvironment: A "Regenerative Program" Hacked.

Authors:  Gerard I Evan; Nasun Hah; Trevor D Littlewood; Nicole M Sodir; Tania Campos; Michael Downes; Ronald M Evans
Journal:  Clin Cancer Res       Date:  2017-04-01       Impact factor: 12.531

Review 9.  CAR T-cell immunotherapy: The path from the by-road to the freeway?

Authors:  Lynsey M Whilding; John Maher
Journal:  Mol Oncol       Date:  2015-10-23       Impact factor: 6.603

10.  Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma.

Authors:  Michelle R Goulart; Jennifer Watt; Imran Siddiqui; Rita T Lawlor; Ahmet Imrali; Christine Hughes; Amina Saad; Joanne ChinAleong; Chris Hurt; Catrin Cox; Roberto Salvia; Alberto Mantovani; Tatjana Crnogorac-Jurcevic; Somnath Mukherjee; Aldo Scarpa; Paola Allavena; Hemant M Kocher
Journal:  NPJ Precis Oncol       Date:  2021-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.